Our Vision In Action
Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost
Our world-class drug discovery team is leveraging our computational platform and massive computing power to advance our preclinical pipeline and a portfolio of programs in collaboration with leading biotech and pharmaceutical companies.
Program | DiscoveryIND-EnablingCLINICAL | Rights |
---|---|---|
Rights Program SGR-1505 (MALT1)Relapsed /
Resistant![]() Non-Hodgkin's Lymphoma |
IND-Enabling
|
Schrödinger |
Program
CDC7Hematological Cancers and Solid Tumors |
Discovery
|
Schrödinger |
Program
Wee1Gynecological Cancers and other Solid Tumors |
Discovery
|
Schrödinger |
Program
UndisclosedOncology |
Discovery
|
Schrödinger |
Program UndisclosedImmunology |
Discovery
|
Schrödinger |
Rights
Program
SOS1 / KRASKRAS-Driven Cancers![]() ![]() |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedOncology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedOncology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedImmunology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program UndisclosedNeurology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Program Protein DegradersOncology,
Immunology and Neurology |
Discovery
|
Schrodinger and Bristol Myers Squibb |
Rights
Program UndisclosedNeurodegenerative Disease![]() ![]() |
Discovery
|
Schrodinger and Takeda |
Program UndisclosedOncology |
Discovery
|
Schrodinger and Takeda |
Rights
Program DNA Damage
ResponseOncology
![]() ![]() |
Discovery
|
Schrodinger and ZAI Lab |
Rights







Collaborative Programs
We have teamed up with venture capitalists, leading academics, and biopharma companies around the globe to establish research collaborations and co-found startups. These collaborations have to date resulted in two FDA approved drugs and multiple programs that have advanced into clinical trials.
COLLABORATOR










Undisclosed
Indication | DiscoveryPRECLINICALPHASE 1PHASE 2PHASE 3FDA APPROVED | COLLABORATOR |
---|---|---|
COLLABORATORINDICATION
![]() |
FDA APPROVED
|
|
COLLABORATORINDICATION
![]() |
FDA APPROVED
|
|
COLLABORATORINDICATION
![]() |
DISCOVERY
|
|
COLLABORATORINDICATION
![]() |
DISCOVERY
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Phase 2
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Phase 2
|
|
COLLABORATORINDICATION
![]() |
Phase 2
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Preclincal
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Discovery
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Phase 1
|
|
COLLABORATORINDICATION
![]() |
Preclinical
|
|
COLLABORATORINDICATION
Undisclosed
Oncology
|
Phase 1
|
* Acquired by Servier
** Acquired by Gilead